# 9-ING-41 in Pediatric Patients With Refractory Malignancies.

> **NCT04239092** · PHASE1 · TERMINATED · sponsor: **Actuate Therapeutics Inc.** · enrollment: 40 (actual)

## Conditions studied

- Refractory Cancer
- Refractory Neoplasm
- Cancer Pediatric
- Refractory Tumor
- Pediatric Cancer
- Pediatric Brain Tumor
- Neuroblastoma
- Neuroblastoma Recurrent
- Pediatric Lymphoma
- Pediatric Meningioma
- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** 9-ING-41
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT04239092
- **Lead sponsor:** Actuate Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-05
- **Primary completion:** 2025-07-07
- **Final completion:** 2025-07-07
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma.
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04239092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04239092, "9-ING-41 in Pediatric Patients With Refractory Malignancies.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04239092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*